Robert E. Hollingsworth

4.9k total citations · 1 hit paper
66 papers, 3.7k citations indexed

About

Robert E. Hollingsworth is a scholar working on Molecular Biology, Oncology and Immunology. According to data from OpenAlex, Robert E. Hollingsworth has authored 66 papers receiving a total of 3.7k indexed citations (citations by other indexed papers that have themselves been cited), including 38 papers in Molecular Biology, 31 papers in Oncology and 14 papers in Immunology. Recurrent topics in Robert E. Hollingsworth's work include Cancer Cells and Metastasis (7 papers), Ubiquitin and proteasome pathways (7 papers) and Immunotherapy and Immune Responses (7 papers). Robert E. Hollingsworth is often cited by papers focused on Cancer Cells and Metastasis (7 papers), Ubiquitin and proteasome pathways (7 papers) and Immunotherapy and Immune Responses (7 papers). Robert E. Hollingsworth collaborates with scholars based in United States, United Kingdom and Canada. Robert E. Hollingsworth's co-authors include Kathrin U. Jansen, Robert A. Sclafani, Kris F. Sachsenmeier, Erin Sult, David Dolberg, Mina J. Bissell, Nicholas Ling, Yuewei Qian, James L. Maller and Thomas A. Langan and has published in prestigious journals such as Nature, Science and Proceedings of the National Academy of Sciences.

In The Last Decade

Robert E. Hollingsworth

64 papers receiving 3.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Turning the corner on therapeutic cancer vaccines

2019 530 citations Robert E. Hollingsworth et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Robert E. Hollingsworth United States	32	2.0k	1.4k	942	411	392	66	3.7k
Chloé C. Féral France	27	1.6k 0.8×	888 0.6×	501 0.5×	472 1.1×	546 1.4×	59	2.9k
Karen E. Pollok United States	38	2.7k 1.4×	1.7k 1.2×	1.6k 1.7×	445 1.1×	671 1.7×	142	5.6k
Mitomu Kioi Japan	23	1.5k 0.7×	909 0.6×	701 0.7×	104 0.3×	488 1.2×	63	3.5k
Edwin Bremer Netherlands	34	1.5k 0.7×	935 0.6×	1.6k 1.7×	191 0.5×	300 0.8×	89	3.1k
Colin Nixon United Kingdom	38	3.0k 1.5×	1.4k 0.9×	727 0.8×	673 1.6×	1.3k 3.3×	94	5.1k
Fawzi Aoudjit Canada	28	1.2k 0.6×	1.0k 0.7×	862 0.9×	304 0.7×	567 1.4×	61	2.7k
Lunquan Sun China	42	3.3k 1.7×	988 0.7×	733 0.8×	296 0.7×	1.3k 3.2×	135	5.2k
Flavio Salazar‐Onfray Chile	34	1.1k 0.5×	1.1k 0.8×	2.1k 2.2×	145 0.4×	232 0.6×	83	3.3k
Mary M. Tomayko United States	21	1.2k 0.6×	1.0k 0.7×	1.8k 2.0×	106 0.3×	389 1.0×	41	4.0k

Countries citing papers authored by Robert E. Hollingsworth

Since Specialization

Citations

This map shows the geographic impact of Robert E. Hollingsworth's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert E. Hollingsworth with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert E. Hollingsworth more than expected).

Fields of papers citing papers by Robert E. Hollingsworth

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robert E. Hollingsworth. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert E. Hollingsworth. The network helps show where Robert E. Hollingsworth may publish in the future.

Co-authorship network of co-authors of Robert E. Hollingsworth

This figure shows the co-authorship network connecting the top 25 collaborators of Robert E. Hollingsworth. A scholar is included among the top collaborators of Robert E. Hollingsworth based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robert E. Hollingsworth. Robert E. Hollingsworth is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Meskini, Rajaâ El, Nathan Pate, Michael D. Oberst, et al.. (2021). Distinct Biomarker Profiles and TCR Sequence Diversity Characterize the Response to PD-L1 Blockade in a Mouse Melanoma Model. Molecular Cancer Research. 19(8). 1422–1436. 3 indexed citations

Rios‐Doria, Jonathan, Jay Harper, Raymond Rothstein, et al.. (2017). Antibody–Drug Conjugates Bearing Pyrrolobenzodiazepine or Tubulysin Payloads Are Immunomodulatory and Synergize with Multiple Immunotherapies. Cancer Research. 77(10). 2686–2698. 91 indexed citations

Rios‐Doria, Jonathan, et al.. (2017). Abstract 4779: Targeting the CCL20-CCR6 axis as a novel opportunity to stimulataneously modulate cancer stem cells and the tumor-immune infiltrate by a dual anti-cancer mechanism. Cancer Research. 77(13_Supplement). 4779–4779. 2 indexed citations

Kerk, Samuel A., Alexander T. Pearson, Kristy A. Warner, et al.. (2016). 5T4-Targeted Therapy Ablates Cancer Stem Cells and Prevents Recurrence of Head and Neck Squamous Cell Carcinoma. Clinical Cancer Research. 23(10). 2516–2527. 40 indexed citations

Xiao, Zhan, Rosa A. Carrasco, Kevin Schifferli, et al.. (2016). A Potent HER3 Monoclonal Antibody That Blocks Both Ligand-Dependent and -Independent Activities: Differential Impacts of PTEN Status on Tumor Response. Molecular Cancer Therapeutics. 15(4). 689–701. 27 indexed citations

Zhong, Haihong, April Davis, Maria Ouzounova, et al.. (2016). A Novel IL6 Antibody Sensitizes Multiple Tumor Types to Chemotherapy Including Trastuzumab-Resistant Tumors. Cancer Research. 76(2). 480–490. 40 indexed citations

Conley, Sarah J., Emily E. Bosco, David A. Tice, et al.. (2016). HER2 drives Mucin-like 1 to control proliferation in breast cancer cells. Oncogene. 35(32). 4225–4234. 31 indexed citations

Zhong, Haihong, Christine Fazenbaker, Shannon Breen, et al.. (2016). Overproduction of IGF-2 drives a subset of colorectal cancer cells, which specifically respond to an anti-IGF therapeutic antibody and combination therapies. Oncogene. 36(6). 797–806. 27 indexed citations

Milagre, Carla, Ganga Gopinathan, Richard G. Thompson, et al.. (2015). Adaptive Upregulation of EGFR Limits Attenuation of Tumor Growth by Neutralizing IL6 Antibodies, with Implications for Combined Therapy in Ovarian Cancer. Cancer Research. 75(7). 1255–1264. 36 indexed citations

10.

Gopinathan, Ganga, Carla Milagre, Oliver M.T. Pearce, et al.. (2015). Interleukin-6 Stimulates Defective Angiogenesis. Cancer Research. 75(15). 3098–3107. 191 indexed citations

11.

Rios‐Doria, Jonathan, Nicholas M. Durham, Leslie Wetzel, et al.. (2015). Doxil Synergizes with Cancer Immunotherapies to Enhance Antitumor Responses in Syngeneic Mouse Models. Neoplasia. 17(8). 661–670. 146 indexed citations

12.

Zhong, Haihong, Christine Fazenbaker, Shannon Breen, et al.. (2014). MEDI-573, Alone or in Combination with Mammalian Target of Rapamycin Inhibitors, Targets the Insulin-like Growth Factor Pathway in Sarcomas. Molecular Cancer Therapeutics. 13(11). 2662–2673. 20 indexed citations

13.

Bid, Hemant K., Cheryl A. London, Haihong Zhong, et al.. (2013). Dual Targeting of the Type 1 Insulin-like Growth Factor Receptor and Its Ligands as an Effective Antiangiogenic Strategy. Clinical Cancer Research. 19(11). 2984–2994. 18 indexed citations

14.

Sachsenmeier, Kris F., Carl Hay, Lori Clarke, et al.. (2012). Development of a Novel Ectonucleotidase Assay Suitable for High-Throughput Screening. SLAS DISCOVERY. 17(7). 993–998. 15 indexed citations

15.

Smith, J. Joshua, et al.. (2002). Apoptotic Regulation by the Crk Adapter Protein Mediated by Interactions with Wee1 and Crm1/Exportin. Molecular and Cellular Biology. 22(5). 1412–1423. 30 indexed citations

16.

Zaphiropoulos, Peter G., Anne Birgitte Undén, Fahimeh Rahnama, Robert E. Hollingsworth, & Rune Toftgård. (1999). PTCH2, a novel human patched gene, undergoing alternative splicing and up-regulated in basal cell carcinomas.. PubMed. 59(4). 787–92. 69 indexed citations

17.

Perry, Sara, et al.. (1997). Engineered mutants of pRB with improved growth suppression potential. Oncogene. 15(23). 2855–2866. 9 indexed citations

18.

Hollingsworth, Robert E. & Robert A. Sclafani. (1993). Yeast pre-meiotic DNA replication utilizes mitotic origin ARS1 independently of CDC7 function. Chromosoma. 102(6). 415–420. 26 indexed citations

19.

Qian, Yuewei, et al.. (1993). A retinoblastoma-binding protein related to a negative regulator of Ras in yeast. Nature. 364(6438). 648–652. 233 indexed citations

20.

Hollingsworth, Robert E., et al.. (1991). RB Protein as a Cellular "Corral" for Growth-promoting Proteins. Cold Spring Harbor Symposia on Quantitative Biology. 56(0). 211–217. 30 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact